Terms: = Pancreatic cancer AND MUTYH, MYH, 4595, ENSG00000132781, hMYH, MGC4416, MYHbeta
28 results:
1. Pan-cancer Interrogation of
Paller CJ; Tukachinsky H; Maertens A; Decker B; Sampson JR; Cheadle JP; Antonarakis ES
JCO Precis Oncol; 2024 Feb; 8():e2300251. PubMed ID: 38394468
[TBL] [Abstract] [Full Text] [Related]
2. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
3. Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.
Sanjaya P; Maljanen K; Katainen R; Waszak SM; ; Aaltonen LA; Stegle O; Korbel JO; Pitkänen E
Genome Med; 2023 Jul; 15(1):47. PubMed ID: 37420249
[TBL] [Abstract] [Full Text] [Related]
4. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
[TBL] [Abstract] [Full Text] [Related]
5. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
Macklin-Mantia SK; Clift KE; Maimone S; Hodge DO; Riegert-Johnson D; Hines SL
J Genet Couns; 2023 Jun; 32(3):598-606. PubMed ID: 36478495
[TBL] [Abstract] [Full Text] [Related]
6. Association of Pathogenic Variants in Hereditary cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract] [Full Text] [Related]
7. mutyh-associated tumor syndrome: The other face of MAP.
Magrin L; Fanale D; Brando C; Corsini LR; Randazzo U; Di Piazza M; Gurrera V; Pedone E; Bazan Russo TD; Vieni S; Pantuso G; Russo A; Bazan V
Oncogene; 2022 Apr; 41(18):2531-2539. PubMed ID: 35422474
[TBL] [Abstract] [Full Text] [Related]
8. pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
Ishida H; Lam AK
Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
[TBL] [Abstract] [Full Text] [Related]
9. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
[TBL] [Abstract] [Full Text] [Related]
10. Disease spectrum of gastric cancer susceptibility genes.
McKinley SK; Singh P; Yin K; Wang J; Zhou J; Bao Y; Wu M; Pathak K; Mullen JT; Braun D; Hughes KS
Med Oncol; 2021 Mar; 38(5):46. PubMed ID: 33760988
[TBL] [Abstract] [Full Text] [Related]
11. Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium.
Boulouard F; Kasper E; Buisine MP; Lienard G; Vasseur S; Manase S; Bahuau M; Barouk Simonet E; Bubien V; Coulet F; Cusin V; Dhooge M; Golmard L; Goussot V; Hamzaoui N; Lacaze E; Lejeune S; Mauillon J; Beaumont MP; Pinson S; Tlemsani C; Toulas C; Rey JM; Uhrhammer N; Bougeard G; Frebourg T; Houdayer C; Baert-Desurmont S
Clin Genet; 2021 May; 99(5):662-672. PubMed ID: 33454955
[TBL] [Abstract] [Full Text] [Related]
12. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden.
Cao Y; Ma Y; Yu J; Sun Y; Sun T; Shao Y; Li J; Shen L; Lu M
Cancer Commun (Lond); 2020 Dec; 40(12):746-751. PubMed ID: 33230973
[TBL] [Abstract] [Full Text] [Related]
13. Identification of Genomic Alterations in Sporadic pancreatic Neurogenic Tumors.
Wang XY; Cai JP; Song LL; Huang CS; Chen W; Huang XT; Chen SF; Liu XY; Yin XY
Pancreas; 2020; 49(10):1393-1397. PubMed ID: 33122531
[TBL] [Abstract] [Full Text] [Related]
14. National recommendations of the French Genetics and cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract.
Dhooge M; Baert-Desurmont S; Corsini C; Caron O; Andrieu N; Berthet P; Bonadona V; Cohen-Haguenauer O; De Pauw A; Delnatte C; Dussart S; Lasset C; Leroux D; Maugard C; Moretta-Serra J; Popovici C; Buecher B; Colas C; Noguès C;
Eur J Med Genet; 2020 Dec; 63(12):104080. PubMed ID: 33039684
[TBL] [Abstract] [Full Text] [Related]
15. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
Krepline AN; Geurts JL; Akinola I; Christians KK; Clarke CN; George B; Ritch PS; Khan AH; Hall WA; Erickson BA; Griffin MO; Evans DB; Tsai S
HPB (Oxford); 2020 Dec; 22(12):1745-1752. PubMed ID: 32354656
[TBL] [Abstract] [Full Text] [Related]
16. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
[TBL] [Abstract] [Full Text] [Related]
17. Characterization of novel genetic alterations in salivary gland secretory carcinoma.
Na K; Hernandez-Prera JC; Lim JY; Woo HY; Yoon SO
Mod Pathol; 2020 Apr; 33(4):541-550. PubMed ID: 31822803
[TBL] [Abstract] [Full Text] [Related]
18. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract] [Full Text] [Related]
19. Base excision repair deficiency signatures implicate germline and somatic
Thibodeau ML; Zhao EY; Reisle C; Ch'ng C; Wong HL; Shen Y; Jones MR; Lim HJ; Young S; Cremin C; Pleasance E; Zhang W; Holt R; Eirew P; Karasinska J; Kalloger SE; Taylor G; Majounie E; Bonakdar M; Zong Z; Bleile D; Chiu R; Birol I; Gelmon K; Lohrisch C; Mungall KL; Mungall AJ; Moore R; Ma YP; Fok A; Yip S; Karsan A; Huntsman D; Schaeffer DF; Laskin J; Marra MA; Renouf DJ; Jones SJM; Schrader KA
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833417
[TBL] [Abstract] [Full Text] [Related]
20. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.
Wong W; Lowery MA; Berger MF; Kemel Y; Taylor B; Zehir A; Srinivasan P; Bandlamudi C; Chou J; Capanu M; Varghese A; Yu KH; Iacobuzio-Donahue CA; Shia J; Klimstra DS; Jarnagin WR; Stadler ZK; O'Reilly EM
Cancer; 2019 May; 125(9):1441-1448. PubMed ID: 30620386
[TBL] [Abstract] [Full Text] [Related]
[Next]
